AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023.
Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics Modulation Technologies and Teknova. Additionally, Mr. McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies Accuray, Somnus Medical Technologies, and Target Therapeutics. Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and an MBA. from The Wharton School, University of Pennsylvania.
“We are thrilled to welcome Bob to our Board of Directors,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “Bob further strengthens our Board with his demonstrated success in the global operations and financial management of publicly held medical device companies. His executive leadership experience will be invaluable as we continue to execute on growth objectives.”
Source: AVITA Medical
